Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birinapant in Chronic Hepatitis B
NCT02288208Phase 1Terminated
- Sponsor
- TetraLogic Pharmaceuticals
- Start
- Nov 2014
- Primary completion
- May 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing Antiviral Therapy & Birinapant with Antiviral Therapy & Placebo (2 arms). Primary endpoint: Number of participants with adverse events up to 13 weeks. Started Nov 2014; status: terminated.
02
Drugs
birinapant
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02288208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02288208.